Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-8 of 8

Sort by

Sort Order Select

Journal Articles

PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation

Anna R. Michmerhuizen, Andrea M. Pesch, Leah Moubadder, Benjamin C. Chandler, Kari Wilder-Romans, Meleah Cameron, Eric Olsen, Dafydd G. Thomas, Amanda Zhang, Nicole Hirsh, Cassandra L. Ritter, Meilan Liu, Shyam Nyati, Lori J. Pierce, Reshma Jagsi, Corey Speers

Mol Cancer Ther (2019) 18 (11): 2063–2073.

https://doi.org/10.1158/1535-7163.MCT-19-0520

Published: 01 November 2019

View articletitled, PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation

Includes: Supplementary data

Journal Articles

A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

Fardokht Abulwerdi, Chenzhong Liao, Meilan Liu, Asfar S. Azmi, Amro Aboukameel, Ahmed S.A. Mady, Thippeswamy Gulappa, Tomasz Cierpicki, Scott Owens, Tao Zhang, Duxin Sun, Jeanne A. Stuckey, Ramzi M. Mohammad, Zaneta Nikolovska-Coleska

Mol Cancer Ther (2014) 13 (3): 565–575.

https://doi.org/10.1158/1535-7163.MCT-12-0767

Published: 09 March 2014

View articletitled, A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

Includes: Supplementary data

Journal Articles

Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment

Jianfeng Lu, Donna McEachern, Haiying Sun, Longchuan Bai, Yuefeng Peng, Su Qiu, Rebecca Miller, Jinhui Liao, Han Yi, Meilan Liu, Anita Bellail, Chunhai Hao, Shi-Yong Sun, Adrian T. Ting, Shaomeng Wang

Mol Cancer Ther (2011) 10 (5): 902–914.

https://doi.org/10.1158/1535-7163.MCT-10-0864

Published: 08 May 2011

View articletitled, Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment

Includes: Supplementary data

Journal Articles

Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa

Yang Meng, Wenhua Tang, Yao Dai, Xiaoqing Wu, Meilan Liu, Qing Ji, Min Ji, Kenneth Pienta, Theodore Lawrence, Liang Xu

Mol Cancer Ther (2008) 7 (7): 2192–2202.

https://doi.org/10.1158/1535-7163.MCT-08-0333

Published: 21 July 2008

View articletitled, Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa

Includes: Supplementary data

Journal Articles

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Sanjeev Shangary, Ke Ding, Su Qiu, Zaneta Nikolovska-Coleska, Joshua A. Bauer, Meilan Liu, Guoping Wang, Yipin Lu, Donna McEachern, Denzil Bernard, Carol R. Bradford, Thomas E. Carey, Shaomeng Wang

Mol Cancer Ther (2008) 7 (6): 1533–1542.

https://doi.org/10.1158/1535-7163.MCT-08-0140

Published: 19 June 2008

View articletitled, Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Includes: Supplementary data

Journal Articles

A novel orally active MDM2 inhibitor (MI-219) activates the p53 pathway and is selectively toxic to tumor cells

Mol Cancer Ther (2007) 6 (11_Supplement): B271.

Published: 01 November 2007

View articletitled, A novel orally active MDM2 inhibitor (MI-219) activates the p53 pathway and is selectively toxic to tumor cells

Journal Articles

BI-33, a novel and potent pan-Bcl-2 inhibitor, induces apoptosis in cancer cells and shows combinational effect with chemo drugs

Feng Jiang, Jianting Long, Sanjeev Shangary, Su Qiu, Meilan Liu, Guozhi Tang, ke Ding, Zaneta Nikolovska-Coleska, Dajun Yang, Shaomeng Wang

Mol Cancer Ther (2007) 6 (11_Supplement): C229.

Published: 01 November 2007

View articletitled, BI-33, a novel and potent pan-Bcl-2 inhibitor, induces apoptosis in cancer cells and shows combinational effect with chemo drugs

Journal Articles

(−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer

Liang Xu, Dajun Yang, Shaomeng Wang, Wenhua Tang, Meilan Liu, Mary Davis, Jianyong Chen, James M. Rae, Theodore Lawrence, Marc E. Lippman

Mol Cancer Ther (2005) 4 (2): 197–205.

https://doi.org/10.1158/1535-7163.197.4.2

Published: 15 February 2005

View articletitled, (−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation

A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment

Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

A novel orally active MDM2 inhibitor (MI-219) activates the p53 pathway and is selectively toxic to tumor cells

BI-33, a novel and potent pan-Bcl-2 inhibitor, induces apoptosis in cancer cells and shows combinational effect with chemo drugs

(−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only